Phaseline

Companies › Criterium

Criterium: clinical trials, targets and expected readouts

3 active drug programs in 39 registered trials: 34 Phase 2, 4 Phase 1, 1 Phase 3; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Eribulin
Tubulin inhibitor
TubulinPhase 2Breast CancerJun 2027
Trastuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 2Breast CancerJun 2027
Fruquintinib
Vascular endothelial growth factor receptor inhibitor
FLT1, FLT4, KDRPhase 2Colorectal Cancer; Metastatic Oesogastric Adenocarcinoma; Gastric Cancer; Hepatocellular Carcinoma …Dec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05177068FruquintinibPhase 2Gastric CancerOncologyOct 2024
NCT06446154FruquintinibPhase 2Hepatocellular CarcinomaOncologyDec 2025
NCT06356584FruquintinibPhase 2Colorectal CancerOncologyOct 2026
NCT06091423FruquintinibPhase 2Gastric Cancer/Gastroesophageal Junction AdenocarcinomaOncologyNov 2026
NCT06685276FruquintinibPhase 2Colorectal Cancer MetastaticOncologyDec 2026
NCT05954429FruquintinibPhase 2Colorectal CancerOncologyDec 2026
NCT06484153FruquintinibPhase 2To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal CarcinomaOncologyDec 2026
NCT06356597FruquintinibPhase 2Colorectal CancerOncologyDec 2026
NCT07491159FruquintinibPhase 1Colorectal CancerOncologyDec 2026
NCT07257653FruquintinibPhase 2Colorectal NeoplasmsOncologyDec 2026
NCT06774222FruquintinibPhase 2Gastric/Gastroesophageal Junction AdenocarcinomaOncologyDec 2026
NCT07334431FruquintinibPhase 1Gastric AdenocarcinomaOncologyDec 2026
NCT07011576FruquintinibPhase 2Colon CancerOncologyJan 2027
NCT06979908FruquintinibPhase 2Metastatic Colorectal CancerOncologyJan 2027
NCT05771181FruquintinibPhase 2Colorectal CancerOncologyFeb 2027
NCT06168786FruquintinibPhase 2Colorectal CancerOncologyFeb 2027
NCT06646588FruquintinibPhase 2Esophageal NeoplasmsOncologyApr 2027
NCT06791083FruquintinibPhase 2Gastric CancerOncologyMay 2027
NCT05458674EribulinPhase 2Breast CancerOncologyJun 2027
NCT05458674TrastuzumabPhase 2Breast CancerOncologyJun 2027
NCT07920224FruquintinibPhase 2Stomach NeoplasmsOncologyJun 2027
NCT05571644FruquintinibPhase 2Colorectal CancerOncologyAug 2027
NCT07888309FruquintinibPhase 2Rectal NeoplasmsOncologySep 2027
NCT05831891FruquintinibPhase 2Non-clear Cell Renal Cell CarcinomaOncologyOct 2027
NCT07392346FruquintinibPhase 2Gastric Cancer Adenocarcinoma MetastaticOncologyNov 2027
NCT07136077FruquintinibPhase 2Minimal Residual DiseaseOncologyDec 2027
NCT07896096FruquintinibPhase 2Refractory Metastatic Colorectal CancerOncologyDec 2027
NCT06889610FruquintinibPhase 2Triple Negative Breast Cancer MetastaticOncologyDec 2027
NCT06992258FruquintinibPhase 2Colorectal CancerOncologyDec 2027
NCT06992258FruquintinibPhase 2Colorectal CancerOncologyDec 2027
NCT07488533FruquintinibPhase 2Non-Clear Cell Renal Cell CarcinomaOncologyDec 2027
NCT06234007FruquintinibPhase 2Locally Advanced Rectal CancerOncologyDec 2027
NCT07130903FruquintinibPhase 2Metastatic Colorectal AdenocarcinomaOncologyApr 2028
NCT06329973FruquintinibPhase 1Metastatic Gastroesophageal Junction AdenocarcinomaOncologyJun 2028
NCT07042685FruquintinibPhase 2Metastatic Colorectal Cancer (CRC)OncologyDec 2028
NCT06980532FruquintinibPhase 1Metastatic Colorectal CancerOncologyDec 2028
NCT06441565FruquintinibPhase 2Colorectal CancerOncologyDec 2029
NCT06856837FruquintinibPhase 2Metastatic Colorectal CancerOncologyDec 2029
NCT07270991FruquintinibPhase 3Metastatic Oesogastric AdenocarcinomaOncologyNov 2030

Targets

Tubulin (1) ERBB2 (1) FLT1 (1) FLT4 (1) KDR (1)

Companies with the same targets

Roche Beijing Biotech Hutchmed Takeda Merck & Co. (MSD) Chia Tai Tianqing Pharmaceutical Group Jiangsu HengRui Medicine Pfizer Sichuan Kelun-Biotech Biopharmaceutical AstraZeneca

Companies built like this

Ryvu Therapeutics GrandPharma (China) EpicentRx Elpiscience (Suzhou) Biopharma Pieris Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.